RxDoctor Payments Data

Taylor Vaughn

Medical · Lakewood, CONPI 1194228288

Payments from drug & device makers

$4,070in general payments, 2019–2025

Across 83 payments — averaging $49.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • AstraZeneca$294
  • Johnson & Johnson$271
  • Astellas Pharma US Inc$158
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$158
  • Novo Nordisk$147
  • plus $879 from 15 others

What the payments were for

  • Travel & lodging$1,48637%
  • Food & beverage$2,51962%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,070 in reported general payments places this provider in the 85th percentile of 766 medical providers in Colorado.

See all medical providers in Colorado

Medicare billing

Part B allowed, 2024
$26,118
Medicare patients
116
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol21$14,059
JardianceEmpagliflozin20$11,557
Potassium Chloride17$458
Calcitriol25$370
Lisinopril46$296
Furosemide34$211
Amlodipine Besylate33$207
Carvedilol22$207
Losartan Potassium37$192
Chlorthalidone14$136
Spironolactone14$108
Hydralazine Hcl18$107
Olmesartan Medoxomil14$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$294$14,05921 claims
Boehringer IngelheimJardiance$2,162$11,55720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 766 medical providers in Colorado.

Other medical in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →